RANOLAZINE IN ISCHEMIC HEART DISEASE
Study results of a new anti-anginal drug (an inhibitor of sodium channels — ranolazine) are presented. Indications, contraindications, major clinical trials of the drug in patients with ischemic heart disease are considered.
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Stolichnaya Izdatelskaya Kompaniya
2015-12-01
|
| Series: | Racionalʹnaâ Farmakoterapiâ v Kardiologii |
| Subjects: | |
| Online Access: | https://www.rpcardio.com/jour/article/view/423 |